| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/14728222.2018.1406925 |
| P698 | PubMed publication ID | 29166798 |
| P50 | author | Giuseppe Rengo | Q38137116 |
| Alessandro Cannavo | Q38321596 | ||
| Leonardo Bencivenga | Q61114285 | ||
| P2093 | author name string | Daniela Liccardo | |
| Klara Komici | |||
| Nicola Ferrara | |||
| Giuseppina Gambino | |||
| Maria Loreta D'amico | |||
| P2860 | cites work | Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association | Q22306345 |
| Molecular basis for activation of G protein-coupled receptor kinases | Q24296928 | ||
| Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts | Q24322049 | ||
| Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure | Q24648449 | ||
| Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice | Q24650383 | ||
| The autonomic nervous system and heart failure | Q27024610 | ||
| Keeping G proteins at bay: a complex between G protein-coupled receptor kinase 2 and Gbetagamma | Q27641311 | ||
| Structure of Human G Protein-Coupled Receptor Kinase 2 in Complex with the Kinase Inhibitor Balanol | Q27659470 | ||
| Paroxetine Is a Direct Inhibitor of G Protein-Coupled Receptor Kinase 2 and Increases Myocardial Contractility | Q27671474 | ||
| 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults | Q28239484 | ||
| The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling | Q28272350 | ||
| Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor | Q28504814 | ||
| Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function | Q28505330 | ||
| Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity | Q28567196 | ||
| G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure | Q30487539 | ||
| The full-length, cytoplasmic C-terminus of the beta 2-adrenergic receptor expressed in E. coli acts as a substrate for phosphorylation by protein kinase A, insulin receptor tyrosine kinase, GRK2, but not protein kinase C and suppresses desensitizati | Q30967052 | ||
| Phosphorylation of GRK2 by protein kinase C abolishes its inhibition by calmodulin. | Q31479337 | ||
| cDNA cloning and chromosomal localization of the human beta-adrenergic receptor kinase. | Q33549904 | ||
| Nebivolol protects against myocardial infarction injury via stimulation of beta 3-adrenergic receptors and nitric oxide signaling | Q33645780 | ||
| Small molecule disruption of G beta gamma signaling inhibits the progression of heart failure | Q34077136 | ||
| Mapping the putative G protein-coupled receptor (GPCR) docking site on GPCR kinase 2: insights from intact cell phosphorylation and recruitment assays | Q34139164 | ||
| AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model | Q34248473 | ||
| A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. | Q34448395 | ||
| GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity | Q34644069 | ||
| Myocardial Ablation of G Protein-Coupled Receptor Kinase 2 (GRK2) Decreases Ischemia/Reperfusion Injury through an Anti-Intrinsic Apoptotic Pathway | Q34785282 | ||
| Molecular basis for small molecule inhibition of G protein-coupled receptor kinases | Q34992803 | ||
| G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. | Q35041039 | ||
| Endothelial dysfunction: a marker of atherosclerotic risk | Q35067247 | ||
| Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. | Q35903753 | ||
| Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors. | Q35981205 | ||
| Reversal of diet-induced obesity and insulin resistance by inducible genetic ablation of GRK2. | Q36100307 | ||
| Integrated Left Ventricular Global Transcriptome and Proteome Profiling in Human End-Stage Dilated Cardiomyopathy | Q36154933 | ||
| Structure-Based Design of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors Based on Paroxetine. | Q36316194 | ||
| GRK2 compromises cardiomyocyte mitochondrial function by diminishing fatty acid-mediated oxygen consumption and increasing superoxide levels | Q36399800 | ||
| Inhibition of G-protein-coupled Receptor Kinase 2 Prevents the Dysfunctional Cardiac Substrate Metabolism in Fatty Acid Synthase Transgenic Mice | Q36548326 | ||
| Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction | Q36623426 | ||
| Myocardial pathology induced by aldosterone is dependent on non-canonical activities of G protein-coupled receptor kinases | Q36651023 | ||
| Prognostic Value of Lymphocyte G Protein-Coupled Receptor Kinase-2 Protein Levels in Patients With Heart Failure | Q36757784 | ||
| Role of the amino terminus of G protein-coupled receptor kinase 2 in receptor phosphorylation | Q37329469 | ||
| GRK2 activation by receptors: role of the kinase large lobe and carboxyl-terminal tail. | Q37347617 | ||
| GRK2 blockade with βARKct is essential for cardiac β2-adrenergic receptor signaling towards increased contractility. | Q37356016 | ||
| Sphingosine-1-phosphate receptor signalling in the heart | Q37413862 | ||
| Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms | Q37470858 | ||
| Convergence of G protein-coupled receptor and S-nitrosylation signaling determines the outcome to cardiac ischemic injury | Q37671204 | ||
| Structural insights into G protein-coupled receptor kinase function. | Q37676935 | ||
| Enhanced GRK2 expression and desensitization of betaAR vasodilatation in hypertensive patients | Q37700344 | ||
| Modulating the NO generating system from a medicinal chemistry perspective: current trends and therapeutic options in cardiovascular disease. | Q37708358 | ||
| Aldosterone: effects on the kidney and cardiovascular system | Q37710377 | ||
| Targeting GRK2 by gene therapy for heart failure: benefits above β-blockade | Q37984182 | ||
| Targeting cardiac β-adrenergic signaling via GRK2 inhibition for heart failure therapy | Q38153376 | ||
| β1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: protective role of S1PR1 cardiac gene therapy | Q38266154 | ||
| Multiple functions of G protein-coupled receptor kinases | Q38599397 | ||
| G protein-coupled receptor kinase 2 promotes cardiac hypertrophy | Q38651555 | ||
| From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure | Q38780801 | ||
| G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitors: Current Trends and Future Perspectives | Q38846772 | ||
| G-Protein-Coupled Receptor Kinase 2 as a Potential Modulator of the Hallmarks of Cancer | Q39022873 | ||
| GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease | Q39080324 | ||
| Obesity-induced cardiac lipid accumulation in adult mice is modulated by G protein-coupled receptor kinase 2 levels. | Q39198039 | ||
| G protein-coupled receptor kinase 2 (GRK2) as an integrative signalling node in the regulation of cardiovascular function and metabolic homeostasis. | Q39227545 | ||
| G protein-coupled receptor kinases (GRKs) in tumorigenesis and cancer progression: GPCR regulators and signaling hubs | Q39284585 | ||
| Cardiac Fibroblast GRK2 Deletion Enhances Contractility and Remodeling Following Ischemia/Reperfusion Injury | Q39416228 | ||
| Increased Epicardial Adipose Tissue Volume Correlates With Cardiac Sympathetic Denervation in Patients With Heart Failure | Q39959976 | ||
| Future g protein-coupled receptor targets for treatment of heart failure. | Q39960928 | ||
| Development of a yeast bioassay to characterize G protein-coupled receptor kinases. Identification of an NH2-terminal region essential for receptor phosphorylation | Q40631683 | ||
| Nucleoside inhibitors of rhodopsin kinase | Q41205865 | ||
| Impact of diabetes mellitus on lymphocyte GRK2 protein levels in patients with heart failure. | Q41643288 | ||
| Synthetic peptides of the hamster beta 2-adrenoceptor as substrates and inhibitors of the beta-adrenoceptor kinase | Q41850423 | ||
| Prodeath signaling of G protein-coupled receptor kinase 2 in cardiac myocytes after ischemic stress occurs via extracellular signal-regulated kinase-dependent heat shock protein 90-mediated mitochondrial targeting | Q41903719 | ||
| An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitro | Q41930742 | ||
| Heart failure: preventing disease and death worldwide | Q42199698 | ||
| Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade | Q42538793 | ||
| Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain | Q43785304 | ||
| Vascular-targeted overexpression of G protein-coupled receptor kinase-2 in transgenic mice attenuates beta-adrenergic receptor signaling and increases resting blood pressure | Q43922014 | ||
| β Adrenergic Receptor Kinase C-Terminal Peptide Gene-Therapy Improves β2-Adrenergic Receptor-Dependent Neoangiogenesis after Hindlimb Ischemia. | Q45880995 | ||
| Vascular endothelial growth factor blockade prevents the beneficial effects of β-blocker therapy on cardiac function, angiogenesis, and remodeling in heart failure | Q46169082 | ||
| Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction | Q46810301 | ||
| Pharmacological and Activated Fibroblast Targeting of Gβγ-GRK2 After Myocardial Ischemia Attenuates Heart Failure Progression | Q47939543 | ||
| Reduction of lymphocyte G protein-coupled receptor kinase-2 (GRK2) after exercise training predicts survival in patients with heart failure. | Q50978052 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 75-83 | |
| P577 | publication date | 2017-11-23 | |
| P1433 | published in | Expert Opinion on Therapeutic Targets | Q5421214 |
| P1476 | title | GRK2 as a therapeutic target for heart failure | |
| P478 | volume | 22 |
| Q92856771 | Aldosterone Jeopardizes Myocardial Insulin and β-Adrenergic Receptor Signaling via G Protein-Coupled Receptor Kinase 2 |
| Q93053027 | Cardioprotective Effects of Dietary Phytochemicals on Oxidative Stress in Heart Failure by a Sex-Gender-Oriented Point of View |
| Q90596638 | Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion |
| Q54978112 | Exploring the relationship between β-adrenergic receptor kinase-1 and physical symptoms in heart failure. |
| Q64229774 | G Protein-Coupled Receptor Kinase 2 (GRK2) as a Potential Therapeutic Target in Cardiovascular and Metabolic Diseases |
| Q92738692 | G protein-coupled receptor kinase 2 (GRK2) as a multifunctional signaling hub |
| Q88796477 | Is GRK2 a new target for cardiovascular disease? |
| Q90720520 | Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies |
| Q91563420 | Molecular signaling of G-protein-coupled receptor in chronic heart failure and associated complications |
| Q64070997 | Periodontal Disease: A Risk Factor for Diabetes and Cardiovascular Disease |
Search more.